title: Antiglaucoma drugs: The role of preservative-free formulations.
abstract: Hypersensitive reactions to eyedrops are a common finding in clinical practice and represent a frequent cause of discontinuation of the therapy. Moreover, experimental and clinical studies show that long term use of topical drugs may induce ocular surface changes causing discomfort and potentially negatively affecting the compliance to the treatment as well as the success rate of filtering procedures. The exact mechanism involved and the roles of the active compound and the preservatives in inducing such detrimental effects of ophthalmic solutions are unclear. During the last years several antiglaucoma agents have been marketed as either preservative-free or benzalkonium chloride-free formulations in an attempt to reduce the adverse effects related to preservatives. This paper summarizes the body of evidence from existing studies about preservatives in antiglaucoma eyedrops, focusing on the latest compounds commercially available. A systematic review of the literature was performed. Current research is focusing not only on the efficacy of the drugs but also on their tolerability. Based on the existing data, there is a rationale to support the use of benzalkonium-free solutions whenever possible, especially in patients suffering from concomitant ocular surface diseases, experiencing local side effects and in those expected to need multiple and prolonged topical treatments.
authors: Eye Clinic, Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Genova, Italy.
authors: Alessandro
authors: A
authors: Bagnis
authors: Marina
authors: M
authors: Papadia
authors: Riccardo
authors: R
authors: Scotto
authors: Carlo E
authors: CE
authors: Traverso
keywords: Benzalkonium chloride; Compliance; Glaucoma medications; Ocular surface toxicity; Preservative-free formulations
references: J Glaucoma. 2004 Apr;13(2):163-7
references: 15097264
references: Eur J Ophthalmol. 2004 Sep-Oct;14(5):407-15
references: 15506603
references: Curr Eye Res. 2003 Oct;27(4):253-9
references: 14562177
references: Br J Ophthalmol. 1998 Jan;82(1):39-42
references: 9536878
references: Surv Ophthalmol. 2001 Mar;45 Suppl 2:S199-202
references: 11587143
references: J Ocul Pharmacol Ther. 2006 Aug;22(4):267-78
references: 16910868
references: Ophthalmology. 2005 Jun;112(6):953-61
references: 15885795
references: Adv Ther. 2011 Jun;28(6):501-10
references: 21603985
references: Arch Ophthalmol. 1994 Nov;112(11):1446-54
references: 7980134
references: Eye (Lond). 2005 Feb;19(2):129-37
references: 15254495
references: Ophthalmology. 2008 Jan;115(1):85-93
references: 17629563
references: Br J Ophthalmol. 2002 Apr;86(4):378-80
references: 11914202
references: Prog Retin Eye Res. 2010 Jul;29(4):312-34
references: 20302969
references: Br J Ophthalmol. 2002 Apr;86(4):418-23
references: 11914211
references: Eur J Ophthalmol. 2007 Jan-Feb;17(1):53-62
references: 17294383
references: Arch Intern Med. 2006 Sep 25;166(17):1829-35
references: 17000938
references: Curr Opin Ophthalmol. 2007 Mar;18(2):134-9
references: 17301615
references: Curr Eye Res. 2011 May;36(5):391-8
references: 21501071
references: Expert Opin Drug Saf. 2007 Jan;6(1):45-52
references: 17181451
references: Ann Rheum Dis. 1998 Jan;57(1):20-4
references: 9536818
references: Curr Opin Ophthalmol. 1996 Apr;7(2):80-6
references: 10163327
references: Lancet. 1999 Nov 20;354(9192):1803-10
references: 10577657
references: Cornea. 2006 Oct;25(9):1046-52
references: 17133051
references: Adv Ther. 2009 Apr;26(4):435-46
references: 19444658
references: Curr Med Res Opin. 2008 Sep;24(9):2663-7
references: 18691444
references: Adv Ther. 2010 Nov;27(11):837-45
references: 20931366
references: J Ocul Pharmacol Ther. 2007 Oct;23(5):481-6
references: 17900227
references: Clin Ophthalmol. 2010 Feb 02;4:1-9
references: 20169043
references: J Glaucoma. 2008 Aug;17(5):350-5
references: 18703943
references: Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2913-21
references: 17525228
references: Br J Ophthalmol. 2006 May;90(5):574-8
references: 16622086
references: Curr Opin Allergy Clin Immunol. 2009 Oct;9(5):447-53
references: 19697451
references: Clin Ophthalmol. 2008 Sep;2(3):613-21
references: 19668762
references: Ophthalmology. 2006 Mar;113(3):431-6
references: 16458967
references: Eur J Ophthalmol. 2007 May-Jun;17(3):341-9
references: 17534814
references: Br J Ophthalmol. 2008 Nov;92(11):1518-21
references: 18782802
references: Cent Eur J Public Health. 2001 Aug;9(3):162-4
references: 11505742
references: Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2525-33
references: 11581193
references: Invest Ophthalmol Vis Sci. 2001 Mar;42(3):642-52
references: 11222522
references: Clin Ophthalmol. 2011;5:623-31
references: 21629567
references: Adv Ther. 2003 Nov-Dec;20(6):329-36
references: 15058750
references: Ophthalmology. 1999 Mar;106(3):556-63
references: 10080214
references: Expert Opin Emerg Drugs. 2011 Jun;16(2):293-307
references: 21406029
references: Acta Ophthalmol. 2008 Nov;86(7):716-26
references: 18537937
references: Australas J Dermatol. 2004 May;45(2):151-2
references: 15068470